Expanding Our Oncotype IQ™ Genomic Intelligence Platform to Transform Patient Management at Every Step of the Cancer Journey
Genetics and genomics are playing an increasingly critical role throughout all stages of cancer care, as evidenced by the impact of Oncotype DX®, our industry-leading portfolio of gene expression tests. Moving forward, Genomic Health will continue to transform cancer management through our development of a new pipeline of that will expand our Oncotype IQ Genomic Intelligence platform to include additional liquid and tissue-based tests for the management and monitoring of multiple cancer types beginning with the recently launched Oncotype SEQ®, a liquid biopsy mutation panel that uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal stromal cancer.
With our new pipeline of gene sequencing and tumour-monitoring tests, we aim to answer a growing number of key patient questions at each of the many stages of cancer, including:
Do I have cancer cells in my body?
What is the precise classification of my cancer?
Is my disease responding to treatment? Is it still responding?
Has my cancer spread or metastasised or become resistant to my current treatment?
Is my disease still in remission?
Which therapy going forward may be the most effective for me?
Is my therapy having the desired effect?
Transforming cancer treatment across the patient journey with our robust product pipeline
Learn more about Genomic Health
Read personal insights from our executives.
See what’s behind our tests, which are improving treatment decisions and providing significant benefit from both a care and cost perspective.
Oncotype IQ Products
Turning insight into action. Learn about the power of the Oncotype IQ product portfolio.